Vanguard Global Advisers
VKTX icon

Vanguard Global Advisers’s Viking Therapeutics VKTX Stock Holding History

Vanguard Global Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Sell
45,368
-1,878
-4% -$60.7K ﹤0.01% 1348
2026
Q1 		$1.54M Buy
+47,246
New +$1.52M ﹤0.01% 1373

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Global Advisers's VKTX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Viking Therapeutics (VKTX) stake by 4% in Q2 2026, selling an estimated $60.7K and leaving 45,368 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1348.

Vanguard Global Advisers first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 428 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Vanguard Global Advisers held 45,368 shares of Viking Therapeutics worth $1.77M as of Q2 2026.
  • Vanguard Global Advisers sold 1,878 Viking Therapeutics shares in Q2 2026, an estimated $60.7K.
  • Viking Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1348 holding.
  • Vanguard Global Advisers first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 428 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.